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Accepted 31 January 2011Ovarian teratoma is generally a benign disease but secondary
malignant transformation within the tumor may take place in
postmenopausal women in rare cases. Squamous cell carci-
noma (SCC) accounts for approximately 80% of the malig-
nant transformations [1]. A possible connection between
SCC arising from an ovarian teratoma and human papillo-
mavirus (HPV) infection was first published by Mai et al.
[2]. To the best of our knowledge, there have only been four
confirmed cases of the high-risk HPV type in ovarian SCC
diagnosed using the HPV typing or staining method [2e5].
Here, we present the case of a woman of childbearing age
diagnosed of ovarian teratoma with SCC malignant trans-
formation. The polymerase chain reaction (PCR)-based
reverse-blot assay, a highly specific method, showed no
expression of HPV in the ovarian SCC but was positive in
the cervix.
A 41-year-old woman, with gravida 1, para 1, had experi-
enced lower abdominal pain for 1 week. Pelvic ultrasound
showed bilateral ovarian teratomas measuring 7.0 6.0
5.4 cm on the left side and 12.0 8.7 5.0 cm on the right.
She underwent a laparotomy with bilateral salpingo-
oophorectomy in August 2009. Pathology proved mature
cystic teratoma of the left ovary, but for the right side it
indicated that there was a dermoid cyst with SCC trans-
formation. Tumor markers, such as carcinoma embryonic
antigen, cancer antigens 125 (CA125) and 199, SCC antigen,
alpha-fetal protein and beta human chorionic gonadotropin,
were normal. She subsequently underwent debulking surgery
with extrafascial hysterectomy, para-aortic and pelvic lymph
node dissection, and partial omentectomy in September 2009.Fig. 1. Lymph node metastases from squamous cell carcinoma. (A) Micro-
scopic sections of lymph node metastases (hematoxylin and eosin 400). (B)
Specific immunostaining is positive for tumor cells (Cytokeratin (CK) 400).
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lymph node (Fig. 1) and no remarkable findings related to the
cervix.
The pathologist took some tumor tissue sections from the
formalin-fixed, paraffin-embedded (FFPE) tissue blocks of the
cervix, the SCC transformation part of the dermoid cyst and
the metastatic lymph node for laboratory analysis. We
extracted the DNA and used the QIAamp DNA FFPE Tissue
Kit (Qiagen Inc., Venlo, The Netherlands) for further purifi-
cation. After using PCR to amplify the HPV DNA in the
specimen, the HPV PCR products were typed in reverse by
using complementary hybridization probes to identify a broad
range of genotypes (Easychip HPV Genotyping Array, King
Car, Taiwan) [6]. The cervix had type-11 HPV expression but
the other two components failed to demonstrate the presence
of any type of HPV (Fig. 2).
The patient had stage IIIc ovarian cancer, so she received
adjuvant chemotherapy with cyclophosphamide and carbo-
platin between September 2009 and January 2010. Regular
follow-up, however, showed an elevated SCC antigen level in
March 2010. Before a complete study into the suspected
ovarian cancer recurrence could take place, the patient diedFig. 2. Polymerase chain reaction-based HPV genotyping array. (A) Chip format of
and two negative controls (NC). (B) Light purple spots indicate HPV type 11 infec
the metastatic lymph nodes were negative for HPV infection.from the disease in April 2010, just 8 months after the
diagnosis.
Germ cell tumors account for 20% of all ovarian tumors
[7]. Most germ cell tumors are mature cystic teratomas that
occur bilaterally in 10.8% of patients [8]. The proportion of
mature cystic teratomas that undergo malignant transformation
is 0.17% [8]. The secondary malignant transformation arising
from an ovarian teratoma often takes time and is most
commonly found in postmenopausal women, with the average
age at diagnosis being 55 years [1]. It is assumed that pelvic
exposure to several carcinogens over time may result in the
malignant transformation of mature tissue [9]. SCC is the most
common type of malignant transformation and accounts for
approximately 80% of cases [1].
The well-known association between cervical SCC and
HPV cannot be ignored in any discussion related to SCC of the
genital tract. While ovarian SCC is rare, the prevalence of
HPV infection and associated cervical SCC is high in sexually-
active women. The worldwide prevalence of HPV without
cervical pathology is around 10.4%. Regional variations exist
and the prevalence of HPV in Asia is 8%. The five leading
types of HPV are HPV 16, 18, 31, 58, and 52 [10]. HPV typeEasychip. There are four systematic controls (SC), two internal controls (IC)
tion of the cervix. (C) Only the control spots shown on the plate indicated that
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being the most common in Taiwan, followed by 16, 51, 35 and
18 [10]. There have been four cases where there has been
a positive connection between ovarian SCC and HPV infec-
tion, where HPV was present in the ovarian SCC without
invasive SCC of the cervix. Some authors concluded that the
similarity of the squamous cells may result in HPV having
the same carcinogenic effect, with HPVof the cervix reaching
the upper genital tract by way of ascending infection [5].
There are also three reported cases that did not find the
presence of HPV in ovarian SCC, where HPV staining or type-
specific DNA hybridization only capable of detecting five
types of HPV was used, yet cervical pathology showed posi-
tive HPVexpression [11e13]. Mai et al. suggested that the low
sensitivity of techniques may result in a failure to demonstrate
the presence of HPV in ovarian SCC [2]. To improve of HPV
typing and detection, we tried a modified MY11/GP6þ PCR-
based reverse-blot array with a reported sensitivity of 96.8%
and a type specificity of 91%. The cervix tissue showed
expression of HPV 11, but the neoplastic tissues, including the
ovarian SCC and the metastatic lymph node, showed no
expression of HPV. It has been suggested that HPV may not
have had an influence on the ovarian SCC in this case,
although the high-risk HPV type for the region may be taken
into consideration.
The staging system for mature cystic teratoma is currently
the same as the International Federation of Gynecology and
Obstetrics (FIGO) classification used for ovarian cancer.
Surgical intervention, including hysterectomy, bilateral
salpingo-oophorectomy and lymphadenectomy, is the main-
stay for the disease. Adjuvant chemotherapy is indicated for
patients with advanced disease. The chemotherapy regimens
are different, however, from those used to treat immature
teratoma and epithelial ovarian cancer. The treatment of
choice for immature teratoma is a combination of bleomycin,
etoposide and cisplatin. The recommended regimens for
advanced epithelial ovarian cancer are carboplatin and pacli-
taxel [14]. For patients experiencing ovarian teratoma with
malignant transformation, alkylating agents result in more
than double the mean survival rate when compared to other
cytotoxic drugs [1]. While the prognosis is fair for early
disease, however, it is still poor in the advanced stage. The 5-
year survival rates for stages I, II, III and IV disease are 95%,
80%, 0% and 0%, respectively [15].
SCC arising from an ovarian teratoma is rare and more
evidence is needed for most effective treatment. The improved
HPV typing method we used utilized HPV staining and some
type-specific in situ hybridization to confirm the negative
result for HPV infection of the ovarian SCC and positive resultfor the cervix. The response to treatment in this case was poor,
despite complete surgery and chemotherapy with an alkylating
agent for stage IIIc disease. We look forward to acquiring
more information about this disease to contribute to our
country database. A more complete database will lead to better
diagnosis, staging and treatment.
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